2. Signaling Pathways
  3. Stem Cell/Wnt
    TGF-beta/Smad
  4. PKA
  5. PKA Isoform
  6. PKA Antagonist

PKA Antagonist

PKA Antagonists (5):

Cat. No. Product Name Effect Purity
  • HY-100530D
    Rp-cAMPS sodium salt
    		Antagonist 99.98%
    Rp-cAMPS sodium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS sodium salt is resistant to hydrolysis by phosphodiesterases.
  • HY-100530
    Rp-cAMPS triethylammonium salt
    		Antagonist 99.53%
    Rp-cAMPS triethylammonium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS triethylammonium salt is resistant to hydrolysis by phosphodiesterases.
  • HY-120994
    Rp-8-CPT-cAMPS sodium
    		Antagonist ≥99.0%
    Rp-8-CPT-cAMPS sodium, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS sodium preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI.
  • HY-120994A
    Rp-8-CPT-cAMPS
    		Antagonist
    Rp-8-CPT-cAMPS, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI.
  • HY-100530A
    Rp-cAMPS
    		Antagonist
    Rp-cAMPS, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS is resistant to hydrolysis by phosphodiesterases.